GSK appeal against fine over 'pay-for-delay' drug deals faces EU rebuke
Share:
BRUSSELS (Reuters) - British drugmaker GlaxoSmithKline may have harmed competition with payments it made to generic drugmakers to delay the launch of cheap copies of an antidepressant, according to an adviser to the European Court of Justice. The legal opinion, which is not binding on the court but carries a significant weight, effectively upholds a penalty of 37.6 million pounds ($49 million) imposed by Britain's competition watchdog in 2016.The Competition and Markets Authority (CMA) said..